Overview

Paliperidone Palmitate Flexible Dosing in Schizophrenia

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or long-acting injectable (LAI) (i.e. with a long duration of action) antipsychotics.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen-Cilag International NV
Treatments:
Paliperidone Palmitate